Inflammation and Impaired Gut Physiology in Post-operative Ileus: Mechanisms and the Treatment Options

Zahid Hussain and Hyojin Park*
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Post-operative ileus (POI) is the transient cessation of coordinated gastrointestinal motility after abdominal surgical intervention. It decreases quality of life, prolongs length of hospital stay, and increases socioeconomic costs. The mechanism of POI is complex and multifactorial, and has been broadly categorized into neurogenic and inflammatory phase. Neurogenic phase mediated release of corticotropin-releasing factor (CRF) plays a central role in neuroinflammation, and affects both central autonomic response as well hypothalamic-pituitary-adrenal (HPA) axis. HPA-stress axis associated cortisol release adversely affects gut microbiota and permeability. Peripheral CRF (pCRF) is a key player in stress induced gastric emptying and colonic transit. It functions as a local effector and interacts with the CRF receptors on the mast cell to release chemical mediators of inflammation. Mast cells proteases disrupt epithelial barrier via protease activated receptor-2 (PAR-2). PAR-2 facilitates cytoskeleton contraction to reorient tight junction proteins such as occludin, Claudins, junctional adhesion molecule, and zonula occludens-1 to open epithelial barrier junctions. Barrier opening affects the selectivity, and hence permeation of luminal antigens and solutes in the gastrointestinal tract. Translocation of luminal antigens perturbs mucosal immune system to further exacerbate inflammation. Stress induced dysbiosis and decrease in production of short chain fatty acids add to the inflammatory response and barrier disintegration. This review discusses potential mechanisms and factors involved in the pathophysiology of POI with special reference to inflammation and interlinked events such as epithelial barrier dysfunction and dysbiosis. Based on this review, we recommend CRF, mast cells, macrophages, and microbiota could be targeted concurrently for efficient POI management.

(J Neurogastroenterol Motil 2022;28:517-530)

Key Words
Ileus; Inflammation mediators; Macrophages; Mast cells; Permeability

Introduction

Post-operative ileus (POI) is the transient cessation of coordinated gastrointestinal (GI) motility after abdominal surgical intervention. It leads to various symptoms such as nausea, vomiting, abdominal discomfort, and inability to pass stools or tolerate a solid diet. In addition to these symptoms, POI is associated with decreased quality of life, prolonged length of stay in a hospital, and increased socioeconomic costs and decreased patients’ satisfaction with surgery.1-4 “Uncomplicated” or “normal” POI is an unavoidable process which generally resolves within 3 days, while
“prolonged” or “paralytic” post-operative ileus extends beyond the duration of 3 days.\textsuperscript{5,7} The mechanism of POI is suggested to be complex and multifactorial, and has been broadly categorized into neurogenic and inflammatory phase.\textsuperscript{6,10} The neurogenic phase is short and ends early after the surgery. The second is the inflammatory phase, which starts 3–4 hours after surgery and persists much longer.\textsuperscript{10,11} Therefore, this review highlights the factors that induce inflammation and how it impairs gut physiology in the POI. It will provide an opportunity and direction for effective management and treatments options to ease the burden of POI.

**Neuroinflammation and Barrier Dysfunction**

Neural pathways are complicated, and are influenced by the number of factors including intensity of the stimulus or stress.\textsuperscript{3,11,12} Briefly, incision of the skin and laparotomy induce the activation of inhibitory spinal and sympathetic reflexes or the adrenergic inhibitory pathway.\textsuperscript{1,2,12} Furthermore, the handling of the bowel stimulates supra-spinal pathway to activate the hypothalamic–pituitary–adrenal (HPA) axis.\textsuperscript{1,2,12} The sensory afferent neurons of this pathway then send signals to the central nervous system to release stress neuropeptides, such as substance P, calcitonin-gene related peptide (CGRP), and corticotropin-releasing factor (CRF).\textsuperscript{11-14} Several studies reported activation of CRF neurons and CRF release in the brain due to the abdominal surgery.\textsuperscript{11,12,15,16} The POI model of our study corroborate these findings, as CRF expression in the hypothalamus increased significantly compared to the control group.\textsuperscript{12} The release of CRF is considered to be a key molecule in neuroinflammation (Fig. 1).\textsuperscript{1,11,12,15-18} This leads to de novo synthesis of central proinflammatory cytokines such IL-1β, IL-6, and TNF-α.\textsuperscript{19,20} CRF triggers stress pathways through receptors, CRF receptor type 1 (CRF1) and type 2.\textsuperscript{21,22} The central CRF is expressed predominantly in the paraventricular nucleus of the hypothalamus,\textsuperscript{21,24} and is involved in alteration of autonomic nervous system activity in the brain to secrete catecholamine to diminish gastric vagal efferent activity and inhibit GI motility.\textsuperscript{25,26} Several studies reported a parallel between central CRF mediated autonomic response as well its ability to activate the HPA-stress-axis.\textsuperscript{27,28} Lenz et al\textsuperscript{27} showed the independence of these 2 pathways in hypophysectomized rats. CRF release activates the HPA axis through pituitary CRF1 receptor that leads to secretion of adrenocorticotropic hormone (ACTH).\textsuperscript{27,28} Similarly, the level of ACTH in POI model of our study was significantly increased compared to healthy controls.\textsuperscript{12} In addition, the higher level of ACTH was

![Schematic illustration of stress–corticotropin-releasing factor (CRF) induced neuroinflammation and barrier disruption with focus on the activation of hypothalamus–pituitary–adrenal (HPA) axis. HPA axis mediated production of cortisol alter gut microbiota, increase lipopolysaccharide (LPS), and impairs gut barrier via reorientation of tight junction proteins. Microbiota alteration also affects its metabolites, ie, short-chain fatty acids to modify epithelial barrier integrity, exacerbate immune cells activation, and add to psychiatric morbidities. ACTH, adrenocorticotropin hormone; DAMPs, damage associated molecular pattern; TLR4, Toll-like receptors-4; PAR-2, protease activated receptor-2; EEC, enteroendocrine cells.](image-url)
directly linked to the inhibition of GI motility. ACTH further activates the adrenal glands to release high levels of cortisol. There is an increasing evidence that shows the involvement of cortisol in dysbiosis and increase in gut permeability. Stress (non-infectious) induced cortisol increased endotoxaemia such as lipopolysaccharides (LPS), and it corresponded LPS from the commensal flora. Interestingly, stress alone could induce adequate LPS from the commensals to initiate the disruption of the intestinal barrier and increase in gut permeability. So a threshold level of CRF or cortisol is enough to initiate the disruption of the intestinal barrier and increase in permeability. It has been reported that corticoid receptors regulates the expression of tight junction proteins (TJPs) such as claudin-1 and occludin. Additionally, dysbiosis decreases bacterial metabolites, short chain fatty acids (SCFAs) such as butyrate, acetate, and propionate to alter gut barrier integrity. Therefore, stress induced cortisol not only alters gut microbiota but also impairs barrier integrity via modifying TJPs (Fig. 1). Impaired gut barrier induces bacterial translocation resulting in activation of the local immune system and inflammation, thereby increasing the release of the cytokines. Several studies reported CRF mediated increase in the expression of Toll-like receptor 4 (TLR4) on macrophages and high level of inflammatory cytokines production via stress induced LPS.

Peripheral Corticotropin-releasing Factor, Immune Cell Activation, and Epithelial Barrier Dysfunction

Recent studies have shown that CRF ligands and receptors are not only expressed in the brain but also in peripheral organs including GI tract. Peripheral CRF (pCRF) is released from cells such as neuronal, enterochromaffin, and immune cells (mast cells) in the lamina propria, submucosa, and muscle layers. CRF1 are expressed by neurons in both myenteric and submucosal plexuses of the enteric nervous system. Interestingly, both central and peripheral administration of CRF and its receptor antagonists results in similar gut transit alterations, though mechanisms and sites of action are distinct. Similarly, we also reported significant increase in GI transit when treated (subcutaneously) with higher doses of selective non-peptide CRF1 antagonist CP-154 526 in a POI model compared to sham controls. Our finding was consistent with previous study that showed the CRF1 antagonist improve delayed gastric emptying induced by laparotomy plus cecal manipulation in mice. Peripheral treatment with human/rat CRF, an agonist for CRF receptor, modifies the delayed GI transit in our POI model. In addition, exogenous CRF induced alterations of gastric transit was reversed by CRF receptor blockade by astressin (a non-selective CRF receptor antagonist). The data from our study strengthen the notion that CRF acts through pCRF pathways, and corroborated earlier findings that CRF is a key player in stress induced gastric emptying and colonic transit. Lenz et al. has shown that the peripherally injected CRF did not activate CRF receptors in the brain. This supports the fact that peripheral release of CRF ligand from afferent nerve terminals and other cells of GI tract is under the influence of autonomic pathways. Several studies reported close proximity of the afferent nerve terminals to the mast cells in the mesentery and mucosa of GI tract (Fig. 2). Peripheral CRF functions as a local effector, and it interacts with the CRF receptors present on mast cells. Peripheral CRF-receptor interactions activate mast cells to degranulate and release chemical mediators such as serine proteases (tryptase) and TNF-α, to impair epithelial barrier integrity via modifying TJPs. However, epithelial barrier disruption via TNF-α and proteases involves different mechanisms. TNF-α enhances epithelial permeability through increased myosin light-chain kinase (MLCK) expression, activation of nuclear factor kappa B (NF-κB) pathway, and reorientation and downregulation of TJPs of the gut. The modified TJPs increase gut permeability, luminal translocation, and immune activation that complements inflammatory cascade.

Mast Cell Protease-mediated Protease Activated Receptor-2 Activation and Barrier Disruption

Neuropeptides such as substance P and CGRP initiate proteases mediated epithelial barrier disruption via protease-activated receptor-2 (PAR-2) signaling mechanisms. PARs are 7 transmembrane-spanning, G-protein-coupled receptors, activated by the cleavage of their N-terminal domain by proteases such as trypsin or trypsin. PAR-2 can be activated by both endogenous and luminal proteases and it is localized on both basolateral and apical sites of enterocytes and is involved in multiple functions including the maintenance of gut permeability (Fig. 2). Activation of either luminal or internal basolateral PAR-2 affects gut paracellular permeability by modulating the degree of cytoskeleton contraction. We explored the role of PAR-2 in POI stress model, and there was an increase in PAR-2 expression in the POI groups compare to sham in the colon. The increase in PAR-2 expression correlated with enhanced initiation and activation of mast cells in the colon. Though there was marked increase in PAR-2 expression
in the colon, it failed to prove statistical significance, indicating that other mediators such as histamines, cytokines, and TNF-α operate along with PAR-2 during the genesis of POI. PAR-2 facilitates cytoskeleton contraction to trigger phosphorylation of myosin light chain catalyzed by the MLCK. Epithelial cell cytoskeletal contraction re-orient TJP s such as occludin, claudins, junctional adhesion molecule-1, and zonula occludens-1, and opening of the epithelial barrier junction. We also identified the changes in gut paracellular permeability through the expression of claudins, and there was decreased expression of claudin-1 but increased expression of claudin-2 in the POI groups compared to sham. Claudins are classified as either barrier-forming or pore forming. Among approximately 24 claudin genes, claudin-1 is known as a barrier-forming protein that decreases paracellular permeability. The other hand, claudin-2 is a pore-forming protein that increases paracellular permeability through the formation of channels. These events affect the selectivity of this pathway and hence permeation of luminal noxious molecules (bacteria, LPS) and solutes in GI tract that induce a perturbation of the mucosal immune system and inflammation. LPS is a ligand of TLR4 on macrophages, and its interaction activates TLR4-cytokine signaling and contributes in the inflammatory cascade.

**Dysbiosis, Inflammatory Response, and Barrier Disruption**

During metabolism, the host and its gut microbiota coproduce a spectrum of metabolites, such as SCFAs that are essential for health. SCFAs mainly consist of acetate, propionate, and butyrate, and it functions through either G protein coupled receptors (GPCRs) or histone deacetylases. SCFAs are a vital fuel for intestinal epithelial cells and are known to strengthen the gut barrier function. Butyrate has been demonstrated to play a key role in the maintenance of the intestinal barrier function and immunomodulation. It also triggers differentiation of colonic regulatory T cells to assist in suppressing inflammatory reactions. Surgical interventions which represents one of the physiologic stress are reported to induce a numerical and compositional shift in the gut microbiota. The relative shift in its composition also affects the bacterial metabolites. The POI model of our study clearly reported a distinct change in the microbial community. The population size of the lactic acid-producing bacteria, including the genera *Bifidobacterium* and *Lactobacillus* decreased, and the population sizes of *Bacteroides* and *Blautia* increased in the POI groups.
study also demonstrated a significant change in the microbial community that reduces the fecal butyrate level. Apart from the POI stress model, repeated water avoidance stress also decreased occludin expression with reduced butyrate-producing microbiota. Parada Venegas et al. clearly showed significant decrease in butyrate-producing bacteria, especially Faecalibacterium prausnitzii, that diminish the SCFAs in feces. Notably, these findings are consistent with previous studies showing that dysbiosis-related decrease in the synthesis of SCFAs was associated with epithelial barrier dysfunction, increased mucosal permeability, and activation of inflammatory response. The exact mechanism associated with immune activation and increase permeability has not been investigated in detail, but probiotics-treated dysbiotic subjects showed restoration of SCFAs and increase the expression of GPCRs such as GPR41, GPR43, and GPR109A on macrophages. SCFAs and receptors interactions facilitate repair of epithelial barrier function and thereby activating anti-inflammatory signaling cascades. Interestingly, Muller et al. demonstrated that luminal microbiota regulate crosstalk between muscularis macrophages (MMs) and enteric neurons to normal regulation of intestinal motility. Related studies also reported severe dysmotility in germ-free rodents, Tlr4–/– and Myd88–/– mice, and our POI model. 

**Prospective Factors That Could Trigger Activation of Macrophages**

Multiple pathways or potential mechanisms activate macrophages to initiate inflammatory phase in POI. First, molecules released in response to cell damage or damage-associated molecular patterns (DAMPs) such as ATP, uric acid, heat-shock proteins, or S100 proteins diffuse in the blood. Dysbiosis through circulation leak out to the site of injury and stimulate muscular monocytes and macrophages. Second, cortisol produced through HPA stress axis alter gut microbial diversity (dysbiosis), and impairs gut barrier via modifying TJPs. Dysbiosis disturbs the crosstalk between MMs and enteric neurons to activate the network of resident macrophages. Third, the activation and degranulation of mast cells in the peritoneal cavity changes its micro-environment. The change in peritoneal environment may directly activate the resident macrophage to release proinflammatory molecules. Fourth, stress induced CRF release, and its interaction with CRF receptors that could stimulate TLR4 on the macrophages. These are some of the major events that would trigger activation of macrophages in surgical intestinal manipulation (Fig. 3).

**Figure 3.** Prospective factors involved in the initiation of inflammatory phase in post-operative ileus (POI). These events or pathways converge to abet vicious cycle of inflammation. DAMPs, damage associated molecular patterns; pCRF, peripheral corticotropin-releasing factor; TJPs, tight junction proteins; LPS, lipopolysaccharide; HSPs, heat shocks proteins; TLR4, Toll-like receptors 4; RAGE, receptor for advanced glycation end products; NF-κB, nuclear factor-kappa B; p38 MAPK, p38 mitogen-activated protein kinase; STAT, signal transducer and activator of transcription; JNK, c-Jun N-terminal kinase; SAP, stress-activated protein; ICAM-1, intercellular adhesion molecules-1; NO, nitric oxide; PGs, prostaglandins; GI, gastrointestinal.
Muscularis Macrophage Activation and Initiation of Intracellular Signaling Pathways

Macrophages play a key role in the pathogenesis of POI. Local inflammation is initiated by macrophages residing in the muscularis layer, which triggers onset of POI (Fig. 4).

These MMs lie in close proximity to neurons within the myenteric plexus, circular and longitudinal smooth muscle layers, and interstitial cells of Cajal. MMs exist in different subsets based on their morphological (stellate and bipolar) structure, however their precise role is still ambiguous.

Stellate resident macrophages are long-lived self-maintaining and arise from both embryonic precursors and adult bone marrow-derived monocytes, and persists throughout adulthood. On the other hand, macrophages lying within the muscle layer exhibit a bipolar morphology. Recently, De Schepper et al demonstrated depletion of self-maintaining macrophages resulted in morphological abnormalities in the submucosal vasculature and loss of enteric neurons, leading to vascular leakage, impaired secretion, and reduced intestinal motility. In the course of surgical stress, the strategic role of self-maintaining MMs had been highlighted and data indicate the central role of MMs in initiating inflammatory cascade. The POI model of our study also demonstrated significant increase in the expression of calprotectin in the muscularis externa and serosa in the colon, while expression in the mucosal layer was insignificant (unpublished data).

The inflammatory cascade of events in the muscularis externa is initiated by MMs via TLR or receptors for advanced glycation end-products within an hour of IM. It activates intracellular signaling pathways such as p38 mitogen-activated protein kinase, c-Jun N-terminal kinases/stress-activated protein, NF-κB, signal transducer and activator of transcription, and extracellular signal-regulated kinase 1/2. These pathways are regulated by series of kinases that

Figure 4. Stepwise events involved in stress induced localized inflammation and barrier dysfunction.

1. Stress induced autonomic nerve stimulation, release of peripheral corticotropin-releasing factor (CRF) and muscularis macrophages receptors activation, further strengthened by damage associated molecular patterns (DAMPs) mediated immune cells activation.
2. Nuclear activation and release of pro-inflammatory chemokines and cytokines.
3. Upregulation of intercellular adhesion molecules-1 (ICAM-1) in the endothelial cells of blood vessels.
4. Influx of leukocytes in the muscularis.
5. Increase synthesis of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) enzymes in the muscularis resident macrophages, release of inflammatory substances (prostaglandins [PGs] and nitric oxide [NO]) in the muscularis to cause localized inflammation.
6. Mast cell and cortisol mediated barrier disruption cause translocation of luminal antigens (lipopolysaccharide [LPS]).
7. LPS induce pathogen associated molecular patterns (PAMPs) mediated activation of mucosal immune cells to further exacerbate inflammation.
8. The luminal antigen drainage through lymphatics and activation of dendritic cells along activation of inhibitory sympathetic and vagal nerve cause generalized inflammation through gastrointestinal tract to induce post-operative ileus. Th, T helper cells; MM, muscularis macrophages; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; SM, smooth muscle; LM, longitudinal muscle.
finally lead to phosphorylation of transcription factors (TFs). The phosphorylated TFs translocate to the nucleus to start the transcription of proinflammatory genes to express cytokines, chemokines, and other inflammatory molecules. Cytokines TNF-α, IL-6, IL-1β, and chemokines (monocyte chemotactant protein-1 and macrophage inflammatory protein-1α [MIP-1α]) are secreted by the resident macrophages. This inflammatory process favors the upregulation of intercellular adhesion molecules (ICAM-1), on the vascular endothelium lining the muscularis. It has been reported that the ICAM-1 mRNA is expressed in the muscularis within 15 minutes of IM, may be triggered by mast cells or DAMPs-mediated activation of MMs. ICAM-1 along with macrophage-derived chemokines initiate the recruitment of circulating leukocytes such as neutrophils and monocytes to the site of injury in the muscularis externa. Kalff et al also showed the influx of leucocytes into the muscularis started approximately 3 hours after manipulation, gradually increasing until 24 hours postoperatively, with monocytes, neutrophils, and mast cells as predominantly infiltrating leucocytes. The POI model of our study showed association between the degree of inflammation and the recovery time of each segment of GI tract. We detected significant increase in the degree of inflammation in each segment of the GI tract, but the highest degree of inflammation was obtained in the colon. These findings were further substantiated by the predominant expression of calprotectin in the colon 6 hours after IM in POI groups. Calprotectin is generally expressed in neutrophils and macrophages, especially activated macrophages and monocytes in the acute inflammatory state. In addition, Snook et al detected the appearance of luminal products in the muscularis externa 6 hours after IM. It validates the observation that translocated bacterial antigens may not trigger muscularis immune responses, but may exacerbate immune responses. The local activated macrophages-mediated molecular inflammatory response is followed by ICAM-1, chemokines-initiated cellular inflammatory phase, leading to the additional recruitment of circulating leucocytes (monocytes and neutrophils) into the muscularis externa. Finally, IM induces the synthesis of enzymes such as inducible nitric oxide synthase and cyclooxygenase-2 in the resident macrophages, which mediate the production of nitric oxide, prostaglandins, and arachidonic acid in the intestinal muscular layer. The influx of leucocytes along with the accumulation of prostaglandins and nitric oxide inhibits smooth muscle contractility. Hence, the role of MMs in triggering inflammatory pathway is further established.

Generalized Inflammation and Inhibition of Contractility in Unmanipulated Segments of Gastrointestinal Tract

However, it remains unclear how local inflammation can lead to a generalized intestinal paralysis. There are few hypotheses that de-
fine this paralysis in unmanipulated area; MMrs release IL-12 and activate memory T helper 1 cells to produce IFN-γ, which in turn migrate to intact areas of the gut and spread inflammation.  
Second, lamina propria macrophages transfer the luminal antigens to dendritic cells, which may not lead to mucosal inflammation.  
The activated dendritic cells drain into the lymphatics to initiate inflammatory cascade in the unmanipulated area, leading to the pathogenesis of POI in unmanipulated areas.

**Treatment Options and Management of Post-operative Ileus**

The review explores and sheds light on neuro-inflammation and related events such as barrier disruption, dysbiosis, and cascading inflammatory reactions. Therefore, these events will be obvious drug targets to manage and treat POI (Fig. 5).

**Attenuation of Hypothalamic–Pituitary–Adrenal Axis to Inhibit Corticotropin-releasing Factor Cascading Affects**

Attenuation of HPA stress axis may be an important drug target. It would probably inhibit the release of CRF or stimulation of supra-spinal pathway during surgical stress.  
Our study exhibited normalizing effect of proinflammatory agent DA-9701 (formulated with Pharbitis semen and Corydalis tuber) on POI model, showing decreased plasma ACTH level and central CRF expression.  
We hypothesize that DA-9701 possibly act through central CRF pathway to improve POI.  
Jung et al. showed that DA-9701 improves delay in gastric emptying and inhibits plasma ACTH level. Furthermore, Ait-Belghaoui et al. exploited a probiotic strain *Lactobacillus farriminis* to attenuate HPA stress axis. The central effects of *L. farriminis* enhance intestinal epithelial barrier and decrease endotoxemia and corticosteronemia.  
Based on their findings HPA regulatory or anti-cortisol myosin light chain regulatory drugs are key to control enterocytes cytoskeleton contraction-related barrier opening (Fig. 5).

**Peripheral Corticotropin-releasing Factor–Corticotropin-releasing Factor Receptors Antagonists**

The activation of CRF signaling pathways are known to play a key role in the pathogenesis of POI.  
Animal studies also established the role of CRF1 in the early phase of postoperative gastric ileus.  
Peripheral CRF increase epithelial permeability which are mediated via TLR4 and cytokine signaling.  
These findings specify a potential new therapeutic venue to alleviate the early phase of postoperative ileus with CRF1 antagonist such as CP-154 526 (Fig. 5).

**Mast Cell Stabilization and Regulation of Protease Activated Receptor-2**

CRF or neuropeptides-activated mast cells release chemical mediators (tryptase) that activate PAR-2 to initiate inflammatory response and disruption of barrier integrity into the pathogenies of POI.  
Therefore, mast cell stabilization should be the earliest strategy to be taken into consideration to restore epithelial barrier integrity, decreased permeability, and ameliorate POI recovery.  
Ketotifen is a mast cell-stabilizing agent that blocks the release of mast cell granules.  
Additionally, PAR-2 receptors should be downregulated to modulate pathways involved in gut permeability to prevent POI. Therefore, PAR-2 is a new target in the therapeutic approach of digestive diseases. One such drug is I-287A, a selective and potent PAR-2 inhibitor for the treatment of inflammation.

**Restoration of Microbial Diversity**

Increasing evidence has indicated that surgical stress causes numerical and compositional shift in the gut microbiota.  
In addition, loss of microbial diversity is involved in surgical complications.  
Therefore, it is imperative to compensate the lost microbial population that could repair intestinal barrier damage and promote anti-inflammatory functions. Our study demonstrated that pretreatment of probiotics before surgery restores the beneficial bacterial species, butyrate production, and bowel movement.  
The modulation of gut microbiota may help the treatment and prevention of POI (Fig. 5). Separately, water avoidance stress-induced changes in TJPs were restored by the administration of butyrate-producing bacteria.  
Parada Venegas et al. reported how empirical modulation of the microbiota using prebiotics or probiotics can increase SCFAs-producing bacteria, hence enriching microbial diversity and improving clinical and histological parameters.

**Maintenance of Tight Junction Proteins**

Gut paracellular permeability is largely determined by alterations of TJPs.  
So, protecting the TJPs will maintain epithelial permeability and hence enhance POI recovery. In the POI model of our study, there was significant change in the expression of claudin-1 and claudin-2 in both the ileum and proximal colon.
Interestingly, glutamine significantly reversed the level of claudin-1 and claudin-2 expression in both the ileum and proximal colon. Glutamine maintains intestinal tissue integrity, and one of the several mechanisms associated with this function is the induction of the expression of TJPs such as claudin-1, occludin, and zonula occludens. In addition, glutamine also exhibits anti-inflammatory effects by modulating the inflammatory signaling pathways such as NF-κB, signal transducer, and activator of transcription pathways (Fig. 5).

Prevention of Macrophage Activation to Inhibit Inflammation

Multiple pathways or potential mechanisms activate macrophages and other immune cells to initiate inflammatory phase in POI. Practically, multi-pronged approach should be applied to deplete and inactivate resident macrophages to limit the inflammatory affect.

Prokinetic Mediated Activation of Cholinergic Anti-inflammatory Pathway

One such approach is the activation of cholinergic anti-inflammatory pathway. In our study, lower dose (0.3 mg/kg) of mosapride significantly decreased the leukocytes infiltration as well as calprotectin expression from activated macrophages and neutrophils. Previous studies indicated anti-inflammatory effect of mosapride that stimulates 5-hydroxytryptamine 4 receptor in myenteric plexus nerve to release acetylcholine (ACh) at the distal end of vagal efferents. ACh in turn inhibits the release of TNF-α, IL-6, MIP-2, and MIP-1α by macrophages through their α7 nicotinic ACh receptors to ameliorate inflammation.

Intracellular Signaling Pathway Inhibitors

Targeting intracellular signaling pathways of the MMs could dampen transcription factors, induction of pro-inflammatory gene expression, and the release of chemokines and cytokines. This may be an interesting alternative approach to treat POI. Semapimod, a p38 mitogen-activated protein kinase inhibitor indeed reduced POI by dampening the expression of the proinflammatory genes MIP-1α, IL-6, MCP-1, and ICAM-1 and deaccelerate leukocytes influx. In addition, inhibition of phosphorylation of TFs could be the prime drug target to abolish POI effects.

Downregulation of Intercellular Adhesion Molecules-1

Once the inflammatory cascade is initiated, adhesion molecules such ICAM-1 is upregulated to attract leucocytes from the circulation to impair smooth muscle contractility. So, a mechanism that prevents ICAM-1 expression, ie, antisense mediated inhibition of ICAM-1, would be an ideal strategy to dampen the effects of POI.

Inhibition of Inflammatory Enzymes

The metabolites of inflammatory enzymes have a huge impact on smooth muscle contractility. Therefore, selective inhibitions of enzymes such as inducible nitric oxide synthase or cyclooxygenase-2 could prevent POI.

Conclusions

Taken together, this review highlights the vast influence of neuroinflammation, altered intestinal permeability, and dysbiosis on the inflammatory cascades during surgical stress. The vicious inflammatory cycle helps in the recruitment of leukocytes and increased production of metabolites into the muscularis to impair the smooth muscle contractility and accelerate the pathogenesis of POI. These mechanistic observations may lay the foundation for the discovery of novel and potential therapeutic agents to alleviate the effects of POI. This review concludes that CRF, mast cells, macrophages and gut microbiota should be targeted concurrently for efficient POI management. However, further studies are needed to verify the pathological role of heterogeneous macrophages in the GI tract as well as its interaction with gut microbiota and enteric neurons. In addition, POI-specific changes in the gut bacterial species need to be recognized among microbial population.

Financial support: None.

Conflicts of interest: None.

Author contributions: Zahid Hussain reviewed the literature and drafted the original manuscript and figures; and Hyojin Park edited the manuscript and provided important clinical and scientific inputs.

References

1. Bauer AJ, Bocckoaens GE. Mechanisms of postoperative ileus. Neurogastroenterol Motil 2004;16(suppl 2):54-60.
2. Luckey A, Livingston E, Taché Y. Mechanisms and treatment of postoperative ileus. Arch Surg 2003;138:206-214.
3. Chapman SJ, Pericleous A, Downey C, Jayne DG. Postoperative ileus following major colorectal surgery. Br J Surg 2018;105:797-810.
4. Iyer S, Saunders WB, SteMKowski S. Economic burden of postoperative ileus associated with colectomy in the United States. J Manag Care
5. Millan M, Biondo S, Fraccalvieri D, Frago R, Golda T, Kreisler E. Risk factors for prolonged postoperative ileus after colorectal cancer surgery. World J Surg 2012;36:179-185.

6. Vather R, Bissett IP. Risk factors for the development of prolonged postoperative ileus following elective colorectal surgery. Int J Colorectal Dis 2013;28:1385-1391.

7. Artiyan A, Nuncio-Mensah JW, Balasubramaniam S, et al. Prolonged postoperative ileus—definition, risk factors, and predictors after surgery. World J Surg 2008;32:1495-1500.

8. de Jonge WJ, The FO, van der Coden D, et al. Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology 2004;127:535-545.

9. Kelb FC, Türler A, Schwarz NT, et al. Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. Ann Surg 2003;237:301-315.

10. Lee YJ, Hussain Z, Huh CW, Lee YJ, Park H. Inflammation, impaired motility, and permeability in a guinea pig model of postoperative ileus. J Neurogastroenterol Motil 2018;24:147-158.

11. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut 2009;58:1300-1311.

12. Jo SY, Hussain Z, Lee YJ, Park H. Corticotrophin-releasing factor-meditated effects of DA-9701 in postoperative ileus guinea pig model. Neurogastroenterol Motil 2018;30:e13385.

13. Park SJ, Choi EJ, Yoon YH, Park H. The effects of prucalopride on postoperative ileus in guinea pigs. Yonsei Med J 2013;54:845-855.

14. Kowalski ML, Kaliner MA. Neurogenic inflammation, vascular permeability, and mast cells. J Immunol 2018;140:3905-3911.

15. Naito Y, Fukuoka J, Tamai S, et al. Biphasic changes in hypothalamic-pituitary-adrenal function during the early recovery period after major abdominal surgery. J Clin Endocrinol Metab 1991;73:111-117.

16. Guigné KA, Uddelman R, Listwak S, Chrousos GP. Effects of immune neutralization of corticotropin-releasing hormone, adrenocorticotropin, and beta-endorphin in the surgically stressed rat. Endocrinology 1988;122:306-310.

17. van Diest SA, Stanisor OJ, Boeckxstaens GE, de Jonge WJ, van den Wijngaard RM. Relevance of mast cell–nerve interactions in intestinal nociception. Biochim Biophys Acta 2012;1822:74-84.

18. Taché Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep 2009;11:270-277.

19. Hagan P, Pode S, Bristow AF. Endotoxin-stimulated production of rat hypothalamic interleukin-1 beta in vivo and in vitro, measured by specific immunoradiometric assay. J Mol Endocrinol 1993;11:31-36.

20. Weiss JM, Sundar SK, Cierpial MA, Ritchie JC. Effects of interleukin-1 infused into brain are antagonized by alpha-MSH in a dose-dependent manner. Eur J Pharmacol 1991;192:177-179.

21. Nozu T, Okumura T. Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome. J Gastroenterol 2015;50:819-830.

22. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 1999;885:312-328.

23. Hauger RL, Rishrough V, Brauns O, Duizenzaeg GM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006;5:453-479.

24. Jiang Z, Rajamanickam S, Justice NJ. CRF signaling between neurons in the paraventricular nucleus of the hypothalamus (PVN) coordinates stress responses. Neurobiol Stress 2019;11:100192.

25. Kurowska M, Sato A, Swenson RS, Takahashi Y. Sympatho-adenal medullary functions in response to intracerebroventricularly injected corticotropin-releasing factor in anesthetized rats. Brain Res 1986;367:250-257.

26. Heymann-Mönninger I, Taché Y, Trauner M, Weiner H, Garrick T. CRF microinjected into the dorsal vagal complex inhibits TRH analog-and kinin acid-stimulated gastric contractility in rats. Brain Res 1991;554:139-144.

27. Lenz HJ, Burlage M, Ruedler A, Gretten H. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology 1988;94:598-602.

28. Arti-Belgnaoui A, Durand H, Cartier C, et al. Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology 2012;37:1885-1895.

29. Grigoriadis DE. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005;9:651-684.

30. Jung YS, Kim MY, Lee HS, Park SL, Lee KJ. Effect of DA-9701, a novel prokinetic agent, on stress-induced delayed gastric emptying and hormonal changes in rat. Neurogastroenterol Motil 2013;25:254-259, e166.

31. Nozu T, Okumura T. Physiological and metabolic syndrome: role of corticotropin-releasing factor-toll-like receptor 4-proinflammatory cytokine signaling. J Neurogastroenterol Motil 2022;28:173-184.

32. Bailey MT, Dowd SE, Galley JD, Huifanghe AR, Allen RG, Lyte M. Stress to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun 2011;25:397-407.

33. Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 2001;48:630-636.

34. Zheng G, Wu SP, Hu Y, Smith DE, Wiley JW, Hong S. Corticotestosterone mediates stress-related increased intestinal permeability in a region-specific manner. Neurogastroenterol Motil 2013;25:e127-e139.

35. Hussain Z, Kim HW, Huh CW, Lee YJ, Park H. The effect of peripheral CRF peptide and water avoidance stress on colonic and gastric transit in guinea pigs. Yonsei Med J 2017;58:872-877.

36. Rodiño-Janeiro BK, Alonso-Cotoner C, Pigrau M, Lobo B, Vicario M, Santos J. Role of corticotropin-releasing factor in gastrointestinal permeability. J Neurogastroenterol Motil 2015;21:33-50.

37. Kelly SP, Chasiotis H. Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured pill epithelium. J Exp Biol 2011;214(Pt 14):2308-2318.
38. Felinski EA, Cox AE, Phillips BE, Antonetti DA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp Eye Res 2008;86:867-878.

39. Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019;9:19603.

40. Zhang J, Song L, Wang Y, et al. Beneficial effect of butyrate-producing Lachnoclostridium on stress-induced visceral hypersensitivity in rats. J Gastroenterol Hepatol 2019;34:1368-1376.

41. Nébot-Vivinus M, Harkat C, Bzioueche H, et al. Multispecies probiotic protects gut barrier function in experimental models. World J Gastroenterol 2014;20:6832-6843.

42. Zong Y, Zhu S, Zhang S, Zheng G, Wiley JW, Hong S. Chronic stress and intestinal permeability: lupilprofen regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human. Neurogastroenterol Motil 2019;31:e13477.

43. Tsatsanis C, Androulidaki A, Alissafi T, et al. Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1. J Immunol 2006;176:1869-1877.

44. Chaniotou Z, Giannogonas P, Theoharis S, et al. Corticotropin-releasing factor regulates TLR4 expression in the colon and protects mice from colitis. Gastroenterology 2010;139:2083-2092.

45. Yuan PQ, Wu SW, Wang L, Taché Y. Corticotropin releasing factor in the rat colon: expression, localization and upregulation by endotoxin. Peptides 2010;31:322-331.

46. von Mentzer B, Murata Y, Ahlstedt I, Lindström E, Martínez V. Functional CRF receptors in BON cells stimulate serotonin release. Biochem Pharmacol 2007;73:805-813.

47. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Yu F, Yoon PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-58.

48. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-58.

49. Tore J, Tuncel N. Mast cells: target and source of neuropeptides. Curr Pharm Des 2009;15:3433-3445.

50. Van Nassauw L, Adriaensen D, Timmermans JP. The bidirectional communication between neurons and mast cells within the gastrointestinal tract. Auton Neurosci 2007;133:91-103.

51. Barbá G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.

52. Park CH, Joo YE, Choi SK, Rew JS, Kim SJ, Lee MC. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea predominant irritable bowel syndrome. J Korean Med Sci 2003;18:204-210.

53. Overman EL, Rivier JE, Moeser AJ. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha. PLoS One 2012;7:e39939.

54. Santos J, Yates D, Guilarte M, Vicario M, Alonso C, Perdue MH. Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. Psychoneuroendocrinology 2008;33:1248-1256.

55. Saunders PR, Santos J, Hansen NP, Yates D, Groot JA, Perdue MH. Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. Dig Dis Sci 2002;47:208-215.

56. Piche T. Tight junctions and IBS: the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil 2014;26:296-302.

57. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-alpha induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004;286:G367-G376.

58. Bueso L, Florianoni J. Protease-activated receptor 2 and gut permeability: a review. Neurogastroenterol Motil 2008;20:580-587.

59. Snook SA, Dhawan S, van Bree SH, et al. Mast cells trigger epithelial barrier dysfunction, bacterial translocation and postoperative ileus in a mouse model. Neurogastroenterol Motil 2012;24:172-184, e91.

60. Jacob C, Yang PC, Darmoul D, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem 2005;280:1936-1948.

61. Nystedt S, Larsson AK, Aberg H, Sundelin J. The mouse proteinase activated receptor-2 cDNA and gene. Molecular cloning and functional

62. Luckey A, Wang L, Jamieson PM, et al. Corticotropin-releasing factor receptor 1-deficient mice do not develop postoperative gastric ileus. Gastroenterology 2003;125:654-659.

63. Leuz HJ, Raedler A, Greten H, Vale WW, Rivier JE. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. Gastroenterology 1988;95:1510-1517.

64. Zhang Y, Feng BS, Oluwole C, et al. Psychological stress induces eosiophils to produce corticotropin releasing hormone in the intestine. Gut 2009;58:1473-1479.

65. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Yu F, Yoon PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-58.

66. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-58.

67. Tore J, Tuncel N. Mast cells: target and source of neuropeptides. Curr Pharm Des 2009;15:3433-3445.

68. Saunders PR, Santos J, Hansen NP, Yates D, Groot JA, Perdue MH. Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. Dig Dis Sci 2002;47:208-215.

69. Piche T. Tight junctions and IBS: the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil 2014;26:296-302.

70. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-alpha induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004;286:G367-G376.

71. Bueso L, Florianoni J. Protease-activated receptor 2 and gut permeability: a review. Neurogastroenterol Motil 2008;20:580-587.
expression. J Biol Chem 1995;270:5950–5955.
72. De Winter BY, van den Wijngaard RM, de Jonge WJ. Intestinal mast cells in gut inflammation and motility disturbances. Biochim Biophys Acta 2012;1822:66-73.
73. Kong W, McConalogue K, Khitin L, et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 1997;94:8884-8889.
74. Cenac N, Garcia-Villar R, Ferrier L, et al. Proteinase-activated receptor 2-induced colonic inflammation in mice: possible involvement of different neurons, nitric oxide, and paracellular permeability. J Immunol 2003;170:4296-4300.
75. Röka R, Demaude J, Cenac N, et al. Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice. Neurogastroenterol Motil 2007;19:57-65.
76. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013;70:631-643.
77. Kofer BM, Kerstetter JE, Insgna KL. Claudins, dietary milk proteins, and intestinal barrier regulation. Nutr Rev 2013;71:60-65.
78. Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Inest Res 2015;13:11-18.
79. Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Altered colonic sensory and barrier functions by secreted phospholipase A2. J Endocrinol 2018;239:241-252.
80. Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats. J Gastroenterol 2017;52:72-80.
81. Daille B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol 2019;16:461-478.
82. Le Poul E, Kerstetter JE, Insgna KL. Claudins, dietary milk proteins, and intestinal barrier regulation. Nutr Rev 2013;71:60-65.
83. Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008;105:16767-16772.
84. Rivière A, Sébè K, Lantin D, Leroy F, de Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016;7:979.
85. Zheng L, Kelly CJ, Battista KD, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol 2017;199:2976-2984.
86. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Dig Dis Sci 2012;57:3126-3135.
87. Pflöger S, Stumpfl F, Penner GB, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci 2012;1258:52-59.
88. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015;9:392.
89. Park JS, Lee EJ, Lee JC, Kim WK, Kim HS. Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways. Int Immunopharmacol 2007;7:70-77.
90. Liähr H, Gerke T, Müller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002;37:458-466.
91. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446-450.
92. Shogan BD, Smith DP, Christlieb S, Gilbert JA, Zaborina O, Alverdy JC. Intestinal anastomotic injury alters spatially defined microbiome composition and function. Microbiome 2014;2:35.
93. Sommovilla J, Zhou Y, Sun RC, et al. Small bowel resection induces long-term changes in the enteric microbiota of mice. J Gastrointest Surg 2015;19:56-64; discussion 64.
94. Shin SY, Hussain Z, Lee YJ, Park H. An altered composition of fecal microbiota, organic acids, and the effect of probiotics in the guinea pig model of postoperative ileus. Neurogastroenterol Motil 2021;33:e13966.
95. Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 2019;10:277.
96. Brown AJ, Goldsworthy SM, Barnes AA, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312-11319.
97. Müller PA, Koscoč B, Rajani GM, et al. Crosstalk between microbiome macromolecules and enteric neurons regulates gastrointestinal motility. Cell 2014;158:300-313.
98. Abrams GD, Bishop JE. Effect of the normal microbial flora on gastrointestinal motility. Proc Soc Exp Biol Med 1967;126:301-304.
99. Anitha M, Vijay-Kumar M, Sitarasan SV, Gewirtz AT, Srivinasan S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 2012;143:1006-1016, e4.
100. Lotze MT, Zeh HJ, Rubartelli A, et al. The grateful dead: damage associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007;220:66-81.
101. Foell D, Witkowski H, Roth J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382-390.
102. Ozaki H, Kawai T, Shuttleworth CW, et al. Isolation and characterization of resident macrophages from the smooth muscle layers of murine small intestine. Neurogastroenterol Motil 2004;16:39-51.
103. de Winter BY, van Nassocau L, De Man JG, et al. Role of oxidative stress in the pathogenesis of septic ileus in mice. Neurogastroenterol Motil 2005;17:251-261.
104. Eskandari MK, Kalif JC, Billiar TR, Lee KK, Bauer AJ. Lipopolysaccharide activates the microbius macrophage network and suppresses circular smooth muscle activity. Am J Physiol 1997;273(3 Pt 1):G727-G734.
105. Hori M, Kita M, Torishashi S, et al. Upregulation of iNOS by COX-2 in muscular resident macrophage of rat intestine stimulated with LPS.
121. Kalff JC, Carlos TM, Schraut WH, Billiar TR, Simmons RL, Bauer AJ, Türler A, Schwarz NT, Türler E, Kalff JC, Bauer AJ. MCP-1 causes de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the Yip JLK, Balasuriya GK, Spencer SJ, Hill-Yardin EL. The role of in- De Schepper S, Verheijden S, Aguilera-Lizarraga J, et al. Self-main- Choi HK, Lee YJ, Lee YH, Park JP, Min K, Park H. Inflammatory Gabanyi I, Muller PA, Feighery L, Oliveira TY, Costa-Pinto FA, Wehner S, Behrendt FF, Lyuteniski BN, et al. Inhibition of macrophage Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okamura T. Repeated water avoidance stress induces visceral hypersensitivity: role of inter- Viola MF, Boekhstaens G. Intestinal resident macrophages: multitask- Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okamura T. Repeated water avoidance stress induces visceral hypersensitivity: role of inter- leukin-1, interleukin-6 and peripheral corticotropin-releasing factor. J Gastroenterol Hepatol 2017;32:1958-1965. Viola MF, Boekhstaens G. Intestinal resident macrophages: multitask-ers of the gut. Neurogastroenterol Motil 2020;32:e13843. Wehner S, Behrendt FF, Lyuteniski BN, et al. Inhibition of macrophage function prevents intestinal inflammation and postoperative ileus in rodents. Gut 2007;56:176-185. Galaviny I, Muller PA, Feighery L, Oliveira TY, Costa-Pinto FA, Muscida D. Neuro-immune interactions drive tissue programming in intestinal macrophages. Cell 2016;164:378-391. Choi HK, Lee YJ, Lee YH, Park JP, Min K, Park H. Inflammatory responses in the muscle coat of stomach and small bowel in the postoperative ileus model of guinea pig. Yorsei Med J 2013;54:1336-1341. De Schepper S, Stakenborg N, Matteoli G, Verheijden S, Boekhstaens GE. Muscularis macrophages: key players in intestinal homeostasis and disease. Cell Immunol 2018;330:142-150. De Schepper S, Verheijden S, Aguilera-Lizaragga J, et al. Self-main- taining gut macrophages are essential for intestinal homeostasis. Cell 2018;175:400-415, e13. Yip JLK, Balasuriya GK, Spencer SJ, Hill-Yardin EL. The role of in- testinal macrophages in gastrointestinal homeostasis: heterogeneity and implications in disease. Cell Mol Gastroenterol Hepatol 2021;12:1701-1718. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2– STAT1 signaling pathway. Nat Immunol 2005;6:844-851. Türler A, Schwarz NT, Türler E, Kalff JC, Bauer AJ. MCP-1 causes leukocyte recruitment and subsequently endotoxin ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002;282:G145-G155. Petitclerc E, Levesque L, Grose JH, Boulelle PE, Marceau F. Patho-logic leukocyte infiltration of the rabbit aorta confers a vasoconstrictor effect to chemo tactic peptides through cyclooxygenase-derived metabolites. J Immunol 1996;156:3426-3434. Kalff JC, Carlos TM, Schraut WH, Billar TR, Simmons RL, Bauer AJ. Surgically induced leukocytic infiltrates within the rat intestinal mus- cularis mediate postoperative ileus. Gastroenterology 1999;117:378-387. Schwarz NT, Beer-Stolz D, Simmons RL, Bauer AJ. Pathogenesis of paralytic ileus: intestinal manipulation opens a transient pathway between the intestinal lumen and the leukocytic infiltrate of the jejunal muscularis. Ann Surg 2002;235:31-40. Kalff JC, Buchholz BM, Eskandari MK, et al. Biphasic response to gut manipulation and temporal correlation of cellular infiltrates and muscle dysfunction in rat. Surgery 1999;126:498-509. Bauer AJ. Mentation on the immunological modulation of gastrointestinal motility. Neurogastroenterol Motil 2008;20(suppl 1):81-90. Aujebor MN, Das AM, Virág L, Flower RJ, Szabó C, Perretti M. Role of resident peritoneal macrophages and mast cells in chesnokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. J Immunol 1999;162:1685-1691. Soehlenlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010;10:427-439. Fournier BM, Parkos CA. The role of neutrophils during intestinal in- flammation. Mucosal Immunol 2012;5:354-366. Kiro YM, Hussain Z, Lee YJ, Park H. Altered intestinal permeability and drug repositioning in a post-operative ileus guinea pig model. J Neurogastroenterol Motil 2021;27:639-649. Bhardwaj RS, Zott C, Zwadlo-Klarwasser G, et al. The calcium- binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions. Eur J Immunol 1992;22:1891-1897. Zwadlo G, Brüggen J, Gerber G, Schlegel R, Song C. Two calcium-binding proteins associated with specific stages of myeloid cell differen- tiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol 1988;72:310-515. Lagasse E, Weissmann IL. Mouse MRP8 and MRP14, two intracel- lular calcium-binding proteins associated with the development of the myeloid lineage. Blood 1992;79:1907-1915. Engel DR, Koscielny S, Wehner S, et al. T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract. Nat Med 2010;16:1407-1413. Stark ME, Bauer AJ, Szurzowski JH. Effect of nitric oxide on circular muscle of the canine small intestine. J Physiol 1991;444:743-761. Türler A, Kalff JC, Moore BA, et al. Leukocyte-derived inducible nitric oxide synthase mediates murine postoperative ileus. Ann Surg 2006;244:220-229. Kalff JC, Schraut WH, Billar TR, Simmons RL, Bauer AJ. Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents. Gastroenterology 2000;118:316-327. Kreiss C, Toegel S, Bauer AJ, Alpha2-adrenergic regulation of NO production alters postoperative intestinal smooth muscle dysfunction in rodents. Am J Physiol Gastrointest Liver Physiol 2004;287:G658-G666. Kreiss C, Birder LA, Kiss S, VanBibber MM, Bauer AJ, COX-2 dependent inflammation increases spinal Fos expression during rodent postoperative ileus. Gut 2003;52:517-530.
139. Koscielny A, Engel D, Maurer J, Hirner A, Kutsa, Kalif JC. Impact of CCR7 on the gastrointestinal field effect. Am J Physiol Gastrointest Liver Physiol 2011;300:G665-G675.
140. Mueller MH, Glatzle J, Kampfjoglou D, Kasparek MS, Grundy D, Kreis ME. Differential sensitization of afferent neuronal pathways during postoperative ileus in the mouse jejunum. Ann Surg 2008;247:791-802.
141. Graham AC, Temple RM, Obar JJ. Mast cells and influenza a virus: association with allergic responses and beyond. Front Immunol 2015;6:238.
142. Avet C, Sturino C, Grastilleur S, et al. The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects. Commun Biol 2020;3:719.
143. Krezalek MA, Skowron KB, Guyton KL, Shakhsheer B, Hyoju S, Alverdy JC. The intestinal microbiome and surgical disease. Curr Probl Surg 2016;53:257-293.
144. dos Santos Rd, Viana ML, Generoso SV, Arantes RE, Davsson Correia MI, Cardoso VN. Glutamine supplementation decreases intestinal permeability and preserves gut mucosa integrity in an experimental mouse model. JPEN J Parenter Enteral Nutr 2010;34:408-413.
145. Gallowitsch-Puerta M, Tracey KJ. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Ann NY Acad Sci 2005;1062:209-219.
146. Tsuchida Y, Hatao F, Fujisawa M, et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via α7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut 2011;60:638-647.
147. Mishra NC, Rir-sima-ah J, Boyd RT, et al. Nicotine inhibits Fc epsilon RI-induced cysteiny leukotrienes and cytokine production without affecting mast cell degranulation through α7/α9/α10-nicotinic receptors. J Immunol 2010;185:588-596.
148. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421;384-388.
149. Wêhner S, Straesser S, Vilz TO, et al. Inhibition of p38 mitogen activated protein kinase pathway as prophylaxis of postoperative ileus in mice. Gastroenterology 2009;136:619-629.
150. The FO, de Jonge WJ, Bennink RJ, van de Wijngaard RM, Boeckxstaens GE. The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice. Br J Pharmacol 2005;146:232-238.